RAD 202
Alternative Names: 177Lu-RAD202; RAD-202Latest Information Update: 07 Oct 2025
At a glance
- Originator Radiopharm Theranostics
- Class Antineoplastics; Immunoconjugates; Radioisotopes; Radiopharmaceuticals; Single-domain antibodies
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 Solid tumours
- Preclinical Breast cancer; Gastric cancer
Most Recent Events
- 01 Oct 2025 Radiopharm Theranostics plans a phase II trial for Solid tumours
- 01 Apr 2025 Pharmacokinetics and adverse events data from a preclinical trial in Breast cancer released by Radiopharm Theranostics
- 26 Feb 2025 Radiopharm Theranostics plans a phase 0 trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) (NCT06824155)